Clinical Trial Detail

NCT ID NCT04207190
Title Talazoparib and Gemtuzumab Ozogamicin for the Treatment of CD33 Positive Relapsed or Refractory Acute Myeloid Leukemia
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Roswell Park Cancer Institute
Indications

acute myeloid leukemia

Therapies

Gemtuzumab ozogamicin + Talazoparib

Age Groups: adult senior

No variant requirements are available.